Ligand validation:5MOZ

NXL: (2S,5R)-1-formyl-5-[(sulfooxy)amino]piperidine-2-carboxamide

NXL is a Ligand Of Interest in 5MOZ designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5MOZ_NXL_A_701	94%	19%	0.067	0.967	1.87	1.56	4	5	0	0	100%	0.9412
5MOZ_NXL_B_308	54%	12%	0.118	0.881	2.35	1.75	4	4	0	0	100%	1
5MOX_NXL_A_301	93%	15%	0.07	0.964	1.98	1.84	4	5	1	0	100%	1
5MNU_NXL_A_301	91%	11%	0.077	0.965	2.42	1.77	4	4	1	0	100%	0.9412
4S2O_NXL_A_301	59%	40%	0.148	0.93	1.04	1.3	1	2	3	0	100%	1
4HBU_NXL_A_301	100%	51%	0.04	0.993	0.56	1.31	-	1	0	0	100%	1
9BZQ_NXL_A_401	99%	38%	0.059	0.986	1.51	0.93	1	-	0	0	100%	1
4S2I_NXL_B_301	96%	11%	0.06	0.97	2.33	1.82	3	4	0	0	100%	1
8EK9_NXL_A_301	94%	10%	0.067	0.968	1.93	2.38	4	5	0	0	100%	1
4S2K_NXL_C_301	94%	16%	0.075	0.974	1.13	2.54	1	7	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.